Recognized

Hadlima, a biosimilar medicine of Humira, is sold by Organon and developed by Samsung Bioepis.

Samsung Bioepis' Humira biosimilar Hadlima (sold by Organon) has successfully been listed in the formulary recommendations list of U.S. Pharmacy Benefit Management (PBM) company Prime Therapeutics.

On July 12 (local time), Prime Therapeutics announced its formulary recommendations list for Humira biosimilars. The list included Hadlima developed by Samsung Bioepis.

Prime Therapeutics listed Amgen’s Humira biosimilar Amjevita, Boehringer Ingelheim’s Cyltezo, and Organon’s Hadlima. Organon is an overseas partner of Samsung Bioepis.

Prime Therapeutics is a medium-sized PBM under the U.S. insurance company BlueCross BlueShield.

Copyright © BusinessKorea. Prohibited from unauthorized reproduction and redistribution